John G. Lemkey is CEO & COO +1 at Odonate Therapeutics, Inc. (ODT). They have made 8 open-market trades across 1 company since 2018, most recently 2020-11-30.
CIK 0001495904
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $32.0M since 2018, never a sale. Across 8 scored buys the stock is up 15.5% at ninety days, and 12.4 points ahead of the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ODT | 3,457 | $4K |
Shares reported on the most recent Form 4, priced at the 2020-12-02 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 63% | 63% |
| Avg Move | +3.0% | +14.9% | +15.5% |
| Alpha | +1.1% | +12.6% | +12.4% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ODT | BUY | 2019-06-26 | 2019-06-28 | $26.00 | $20.0M | -0.7% | +5.2% | -29.8% |
| ODT | BUY | 2019-06-06 | 2019-06-10 | $27.52 | $3.6M | +9.0% | +51.1% | +23.4% |
| ODT | BUY | 2019-03-07 | 2019-03-11 | $18.32 | $4.7M | +10.1% | +30.3% | +29.6% |
| ODT | BUY | 2018-12-20 | 2018-12-26 | $12.60 | $756K | +18.1% | +44.1% | +75.6% |
| ODT | BUY | 2018-12-14 | 2018-12-18 | $14.67 | $848K | -3.0% | +20.6% | +57.4% |
| ODT | BUY | 2018-10-23 | 2018-10-25 | $15.44 | $919K | +7.9% | -2.7% | +5.9% |
| ODT | BUY | 2018-08-21 | 2018-08-23 | $19.47 | $292K | -9.1% | -4.6% | -25.8% |
| ODT | BUY | 2018-02-28 | 2018-03-02 | $27.42 | $770K | -8.2% | -24.9% | -12.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.